Axa S.A. Purchases 92,567 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Axa S.A. raised its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 27.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 425,334 shares of the biopharmaceutical company’s stock after buying an additional 92,567 shares during the quarter. Axa S.A. owned about 0.46% of Ultragenyx Pharmaceutical worth $17,481,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in RARE. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in shares of Ultragenyx Pharmaceutical by 513.8% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 507,095 shares of the biopharmaceutical company’s stock worth $23,677,000 after buying an additional 424,476 shares during the last quarter. Clearbridge Investments LLC raised its stake in Ultragenyx Pharmaceutical by 0.7% during the first quarter. Clearbridge Investments LLC now owns 2,400,854 shares of the biopharmaceutical company’s stock worth $112,096,000 after acquiring an additional 17,362 shares in the last quarter. Rafferty Asset Management LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 21.2% in the 4th quarter. Rafferty Asset Management LLC now owns 221,910 shares of the biopharmaceutical company’s stock valued at $10,612,000 after purchasing an additional 38,859 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Ultragenyx Pharmaceutical by 3.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,568,873 shares of the biopharmaceutical company’s stock valued at $166,632,000 after purchasing an additional 120,175 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new position in Ultragenyx Pharmaceutical during the 1st quarter worth approximately $1,074,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on RARE. Cantor Fitzgerald restated an “overweight” rating and issued a $116.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Monday, September 16th. Bank of America reduced their price objective on Ultragenyx Pharmaceutical from $83.00 to $76.00 and set a “buy” rating on the stock in a research report on Friday, May 31st. Wedbush increased their target price on Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the company a “neutral” rating in a research report on Friday, August 2nd. The Goldman Sachs Group boosted their price target on Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Finally, Stifel Nicolaus raised their price objective on shares of Ultragenyx Pharmaceutical from $124.00 to $127.00 and gave the company a “buy” rating in a report on Friday, May 31st. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.43.

Ultragenyx Pharmaceutical Trading Down 1.4 %

Shares of Ultragenyx Pharmaceutical stock opened at $54.43 on Friday. The company has a market cap of $4.52 billion, a P/E ratio of -6.78 and a beta of 0.56. The business has a 50-day moving average price of $53.28 and a two-hundred day moving average price of $46.69. Ultragenyx Pharmaceutical Inc. has a 1-year low of $31.52 and a 1-year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.64) by $0.12. The business had revenue of $147.03 million during the quarter, compared to the consensus estimate of $123.20 million. Ultragenyx Pharmaceutical had a negative return on equity of 266.02% and a negative net margin of 121.57%. The firm’s revenue for the quarter was up 35.7% on a year-over-year basis. During the same period in the previous year, the company posted ($2.25) earnings per share. Equities research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -6.24 EPS for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total value of $1,117,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,223,985 shares in the company, valued at $124,209,562.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 40,675 shares of company stock worth $2,149,446 in the last quarter. Company insiders own 5.80% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.